Two pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious alliance to develop new cancer therapies.
Cellectis’ 'off the shelf' CAR-T cancer therapy has hit a major setback after the first patient treated in a phase 1 study died, and the first patient treated in another developed life-thr
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.